Grail (NASDAQ:GRAL – Get Free Report) released its earnings results on Thursday. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55, Zacks reports. The business had revenue of $38.25 million for the quarter, compared to analysts’ expectations of $35.33 million.
Grail Stock Performance
Shares of GRAL opened at $51.29 on Friday. The business’s fifty day moving average price is $26.32 and its 200 day moving average price is $19.06. Grail has a 12-month low of $12.33 and a 12-month high of $63.99.
Analysts Set New Price Targets
GRAL has been the subject of several research analyst reports. Morgan Stanley initiated coverage on Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price for the company. Wolfe Research initiated coverage on Grail in a research note on Friday, November 15th. They set a “peer perform” rating for the company.
About Grail
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Stories
- Five stocks we like better than Grail
- Short Selling: How to Short a Stock
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- Why Invest in High-Yield Dividend Stocks?
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
